Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Clinical trial NCT01278342 · COMPLETED
Trial details
- NCT number
- NCT01278342
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2006-09-01
- Primary completion
- 2009-11-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.